| Literature DB >> 29786651 |
Manal El-Khadragy1,2,3, Ebtesam M Alolayan4,5, Dina M Metwally6,7,8, Mohamed F Serag El-Din9,10, Sara S Alobud11, Nour I Alsultan12, Sarah S Alsaif13,14, Manal A Awad15, Ahmed E Abdel Moneim16.
Abstract
Leishmaniasis is one of the most significant vector-borne syndromes of individuals. This parasitic infection can be affected by many species of Leishmania, most of which are zoonotic. Natural products have made and are continuing to make important contributions to the search for new antileishmanial agents. The use of plants in the production assembly of silver nanoparticles has drawn attention because of its rapid, eco-friendly, non-pathogenic, economical protocol and provides a single step technique for the biosynthetic process. Hence, we aimed to biosynthesize silver nanoparticles (Ag-NPs) using Moringa oleifera leaf extract and investigated the antileishmanial activity of these nanoparticles in a murine model of Leishmania major infection. A total of 50 mice were used and divided into five groups-healthy control, infected, infected mice treated with pentostam, infected mice treated with Ag-NPs and infected mice pretreated with Ag-NPs. In the present study, the leaf extract of the plant species Moringa oleifera was found to be a good source for the synthesis of silver nanoparticles, their formation being confirmed by color change and stability in solution. In the present murine model of Leishmania major infection, we found that oral treatment with silver nanoparticles biosynthesized using Moringa oleifera extract resulted in a significant reduction in the average size of leishmaniasis cutaneous lesions compared with untreated mice. Furthermore, the clinical efficacy of Moringa oleifera extract was associated with enhanced antioxidant enzyme activities. In conclusion, treatment with silver nanoparticles biosynthesized using Moringa oleifera extract has higher and faster clinical efficacy than standard pentavalent antimonial treatment, probably by boosting the endogenous antioxidant activity.Entities:
Keywords: Moringa oleifera; antioxidant; cutaneous leishmaniasis; gene expression; silver nanoparticles
Mesh:
Substances:
Year: 2018 PMID: 29786651 PMCID: PMC5982076 DOI: 10.3390/ijerph15051037
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Experimental determinations of total phenolic and flavonoids contents and antioxidant capacity assays (ABTS, DPPH and FRAB) for Moringa oleifera extract.
| Parameters | Mean ± SD |
|---|---|
| Total phenols (mg eq. Gallic acid/g sample) | 9.466 ± 0.754 |
| Total flavonoids (mg eq. Rutin/g sample) | 0.609 ± 0.026 |
| DPPH (%) | 36.88 ± 0.99 |
| ABTS (μmol eq. Trolox/g sample) | 4.989 ± 0.034 |
| FRAB (μmol eq. Trolox/g sample) | 0.185 ± 0.0005 |
Figure 1(a) The absorption spectrum of the green silver nanoparticles synthesized with Moringa oleifera leaf extract; (b) Presents a graph of a zeta sizer for measuring the average size of green silver nanoparticles.
Figure 2Presents a graph of transition electron microscopy (TEM) image of green silver nanoparticles synthesized (scale bar: 200 nm).
Figure 3Cutaneous lesions of inoculated infected mouse in untreated group (a); Ag-NPs treatment starting when the ulcerative lesion was appeared (b) and Ag-NPs treatment starting two weeks before the infection (c).
Figure 4Lesion size in mouse skin one, two, three and four weeks after infection. Lesion sizes, measured with a digital caliper as described in the Material and Methods. Each point represents the mean ± SEM (n = 10).
Figure 5Effect of Ag-NPs biosynthesized by Moringa oleifera leaf extract pre-treatment or post-treatment and pentostam on oxidative stress markers (malonaldyhide, nitric oxide and glutathione) of control and experimental groups four weeks after infection. Values are mean ± SEM (n = 10), a p < 0.05, significant change compared to –ve Control group; b p < 0.05, significant change compared to +ve Control group. MDA: malonaldyhide; NO: nitric oxide and GSH: glutathione.
Figure 6Effect of Ag-NPs biosynthesized by Moringa oleifera leaf extract pre-treatment or post-treatment and pentostam on dermal antioxidant enzyme activities (superoxide dismutase, catalase and glutathione peroxidase) of control and experimental groups four weeks after infection. Values are mean ± SEM (n = 10), a p < 0.05, significant change compared to –ve Control group; b p < 0.05, significant change compared to +ve Control group. SOD: superoxide dismutase and CAT: catalase, GPx: Glutathione peroxidase.
Figure 7Effect of Ag-NPs biosynthesized Moringa oleifera leaf extract pre-treatment or post–treatment and pentostam on dermal pro-apoptotic and anti-apoptotic proteins (Bcl–2 and Bax) in control and experimental groups. Values are mean ± SEM (n = 10), a p < 0.05, significant change compared to –ve Control group; b p < 0.05, significant change compared to +ve Control group. Bax: Bcl–2–associated X protein and Bcl–2: B–cell lymphoma 2.